GE Healthcare Announces Global Launch of Biomolecular Imagers, Alliance with Fujifilm

GE Healthcare (Chalfont St., Giles, UK), a unit of General Electric Co., announced the global launch of the first biomolecular imaging systems developed as part of its strategic alliance with Fujifilm (Tokyo, Japan). The announcement comes just five months after signing the alliance agreement.

The four systems being launched comprise two laser scanning and two charge-coupled device (CCD) camera-based imagers, which together address a wide range of radioisotopic, fluorescent, and chemiluminescent imaging applications in the life sciences field. In combination with proprietary Amersham enhanced chemiluminescent (ECL) reagents, CyDye chemistries, and image analysis-software products, GE Healthcare can provide extensive imaging products to life scientists to support differing levels of assay complexity and budget.

The versatile imagers, which are the Typhoon FLA 9000, Typhoon FLA 7000, ImageQuant LAS 4000, and the ImageQuant LAS 4000 mini, are designed to support a wide range of applications, with the flexibility to adapt to future applications. GE's global service and support network will be available to provide cover for all imagers sold under the GE brand.

"We aim to provide scientists with comprehensive system solutions for research, drug discovery, and bioanalytical applications,” said Nigel Darby, general manager biotechnologies, GE Healthcare, "Furthermore, the integration of the imaging platforms with our global service organization gives valuable support.”

GE Healthcare provides transformational medical technologies. The company has expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, drug discovery, biopharmaceutical manufacturing technologies, performance improvement, and performance solutions services.

Related Links:
GE Healthcare
Fujifilm